Pharma Update
Roche
Our achievements
Roche is continuously shifting the standard of care
A legacy of patient and business
impact...
Blockbuster drugs in 2022, up
from 7 in 2012
in neurology and hemophilia A¹
16
#1
#3
in oncology1
#1
in in vitro diagnostics1
#1
top pharma as ranked by rare.
#1
disease patient groups²
Pharma in Al readiness³
...with a track record of establishing standard of care
across new therapeutic areas
OCREVUS
ocrelizumab FOR N
300MG/10ML
First and only therapy
approved for RMS/PPMS
HEMLIBRA
emicizumab-kxwh
injection for subcutaneous use
150
mg/mL
First and only prophylactic
treatment for hemophilia A
with/without inhibitors
VABYSMO
First bispecific antibody in
AMD and DME
60 mg
powder for solution
Evrysdi
risdiplam
First-in-class splicing
modifier for the treatment
of SMA
1 based on FY 2022 sales (Evaluate/Bloomberg); 2Patient View, 2023; 3CBInsight, 2023; Al-artificial intelligence; RMS=relapsing; PPMS-primary progressive multiple sclerosis; AMD-age-related macular degeneration;
DME=diabetic macular edema; SMA-spinal muscular atrophy
13View entire presentation